systemic anaplastic large cell lymphoma
Haematology · 2014–2014
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brentuximab vedotin Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) who are suitable for further systemic curative intent… | Mar 2014 | Recommended with restriction | input received Lymphoma Australia · Medical Oncology Group |
Who spoke
Lymphoma Australia · Medical Oncology Group
What the PBS pays
$21M in government benefit over 2024–25, across 1,496 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| brentuximab vedotin | $21.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.